Effects of cannabidiol in alcohol use disorder patients with and without co‐occurring post‐traumatic stress disorder: Tolerability but no evidence for efficacy in two randomized proof‐of‐concept trials
These findings support the feasibility and tolerability of twice-daily oral CBD up to 1200 mg/day in actively drinking individuals but do not demonstrate efficacy at the CBD levels that were achieved in this study. Further dose finding and larger, well-powered trials are needed to clarify CBD's therapeutic potential in AUD and comorbid PTSD.
Authors
- D. Dgheim
- Eugene Laska (ORCID: https://orcid.org/0000-0001-6799-1361)
- Charles R. Marmar (ORCID: https://orcid.org/0000-0001-8427-5607)
- Esther Blessing (ORCID: https://orcid.org/0000-0002-7961-8844)
- Dayeon Cho
- Michael P. Bogenschutz (ORCID: https://orcid.org/0000-0003-4530-3470)
- Jun Zhang (ORCID: https://orcid.org/0000-0002-4479-694X)
Institutions
- New York University (US)
Publication Details
- Journal
- Alcohol Clinical and Experimental Research
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1111/acer.70212
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00